Alec C. Kimmelman

Alec C. Kimmelman, MD, PhD, is chief executive officer of NYU Langone Health and dean of NYU Grossman School of Medicine. He leads one of the largest health systems in the Northeast—employing more than 53,000 people, stretching across 7 inpatient facilities and over 320 locations throughout the New York City region and in Florida. As one of the most renowned health systems in the United States, NYU Langone has been ranked the No. 1 comprehensive academic medical center for quality care in the United States for three years in a row by Vizient Inc. and has earned top accolades from other independent organizations, such as The Leapfrog Group, U.S. News & World Report (Best Hospitals), and the Centers for Medicare & Medicaid Services.

Prior to being appointed CEO and dean in 2025, Dr. Kimmelman served as director of NYU Langone’s Laura and Isaac Perlmutter Cancer Center. In addition, he was the Laura and Isaac Perlmutter Professor of Radiation Oncology, chair of the Department of Radiation Oncology, and the associate dean of cancer research at NYU Grossman School of Medicine. Under his leadership, Perlmutter Cancer Center established its Center for Molecular Oncology in October 2024, which is redefining the standard of cancer care. He and his team built and expanded disease centers, developed multiple research and clinical programs, significantly increased the depth and breadth of cancer services offered at NYU Langone sites, and improved access to clinical trials. As a physician–scientist, Dr. Kimmelman has unique insight into how each pillar of NYU Langone’s mission to care, to teach, to discover can be integrated and harnessed to fuel innovation across the institution.

With more than 20 years of cancer research experience and over 100 peer-reviewed publications, Dr. Kimmelman is one of the foremost experts on the biology of pancreatic cancer. His own research has served to define the metabolic landscape of pancreatic cancer, and his findings have paved the way for multiple clinical trials to treat the disease.

Dr. Kimmelman also serves as an ad hoc reviewer and editorial board member of several leading scientific journals. His research has been published in many prestigious journals, including Cell, Science, Nature, Cancer Cell, Cancer Discovery, and Genes & Development. He has received numerous honors and awards, including the Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research from Columbia University—for the researcher who has made the most significant contribution to pancreatic cancer research—֫and Outstanding Investigator Award from the National Cancer Institute. He was also elected to the American Society for Clinical Investigation and the Association of American Physicians. In 2021, Dr. Kimmelman was named as one of the world’s most influential researchers by Clarivate, a recognition for authoring papers that were in the top 1 percent of his field.

Dr. Kimmelman joined NYU Langone in 2016 as chair of the Department of Radiation Oncology at NYU Grossman School of Medicine and professor of oncology. Prior to joining NYU Langone, Dr. Kimmelman ran a vibrant research program at Dana-Farber Cancer Institute focused on pancreatic cancer. He was also an attending physician at Brigham and Women’s Hospital and Dana-Farber, where he specialized in gastrointestinal malignancies, including pancreatic cancer.

A board-certified radiation oncologist, Dr. Kimmelman earned his MD and PhD from the former Mount Sinai School of Medicine before joining Harvard Medical School as a clinical fellow and completed his training in radiation oncology, as well as a postdoctoral fellowship at Dana-Farber.